Ann McCann

Ann McCann

Auto-generated profile, based on publicly available information

Ann McCann

Department of Medical Physics and Clinical Engineering, St. Vincent's University Hospital, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 November 2021 in Journal of Radiological Protection
Verified
Journal Article
Open access
AMAnn McCann
Ann McCann
LVLuis León Vintró
Luis León Vintró
SCSeán Cournane
Seán Cournane
JLJulie Lucey
Julie Lucey
18F has been the most widely used radionuclide in positron emission tomography (PET) facilities over the last few decades. However, increased interest in novel PET tracers, theranostics and immuno-PET has led to significant growth in clinically used positron-emitting radionuclides. The decay schemes of each of these radioisotopes are markedly different from 18F, with different endpoint energies for the emitted positrons and, in some cases, additional high energy gamma radiation. This has implications for the occupational exposure of personnel involved in the manipulation and dispensing of PET radiopharmaceuticals. The EGSnrc Monte Carlo simulation software was used to estimate the doses to extremities in contact with unshielded and shielded syringes containing 64Cu, 18F, 11C, 13N, 15O, 68Ga and 89Zr, respectively. Dose rates at various distances from the syringe were also modelled, with dose rates reported in terms of eye (Hp(3)), skin equivalent (Hp(0.07)) and deep (Hp(10)) doses. The composition and geometry of the simulated syringe shields were based on a selection of commercially available PET shields. Experimental dose rate measurements were performed for validation purposes where possible. Contact skin dose rates for all isotopes, except for 64Cu, were found to be higher than 18F for the unshielded syringe. The addition of a shield resulted in approximately equal contact skin dose rates for nearly all isotopes, for each shield type, with the exception of 89Zr which was notably higher. Dose rate constants (µGy/MBq.hr) for a range of PET isotopes and shields are presented and their significance discussed.

1 February 2023 in Journal of Radiological Protection
Verified
Journal Article
Open access
PDF file
AMAnn McCann
Ann McCann
NCNicolas Cherbuin
Nicolas Cherbuin
PCPeter Covens
Peter Covens
JDJérémie Dabin
Jérémie Dabin
SHSigalit Haruz-Waschitz
Sigalit Haruz-Waschitz
RKRobert Kollaard
Robert Kollaard
Introduction: Although the use of 68Ga has increased substantially in nuclear medicine over the last decade, there is limited information available on occupational exposure due to 68Ga. The purpose of this study is to determine the occupational extremity exposure during the preparation, dispensing and administration of 68Ga-labelled radiopharmaceuticals. Method: Workers in eight centres wore a ring dosimeter for all tasks involving 68Ga-labelled radiopharmaceuticals for a minimum of one month. Additionally, the fingertip dose was monitored in two centres and the hand with the highest ring dose during 68Ga procedures was also identified in one centre. Results: The median normalised ring dose for 68Ga procedures was found to be 0.25 mSv GBq−1 (range 0.01–3.34). The normalised 68Ga ring doses recorded in this study are similar to that found in the literature for 18F. This study is consistent with previous findings that the highest extremity dose is found on the non-dominant hand. A limited sub study in two of the centres showed a median fingertip to base of the finger dose ratio of 4.3. Based on this median ratio, the extrapolated annual 68Ga fingertip dose for 94% of the workers monitored in this study would be below Category B dose limit (150 mSv) and no worker would exceed Category A dose limit (500 mSv). Conclusion: When appropriate shielding and radiation protection practices are employed, the extremity dose due to 68Ga is comparable to that of 18F and is expected to be well below the regulatory limits for the majority of workers.

8 November 2023 in Physica Medica
Verified
Journal Article
Closed access
AZA. Zorz
A. Zorz
Nicolas CherbuinNicolas Cherbuin
Nicolas Cherbuin
PCPeter Covens
Peter Covens
LCL. Cunha
L. Cunha
AMA. Mccann
A. Mccann
RKR. Kollaard
R. Kollaard

27 August 2025 in Physica Medica
Verified
Journal Article
Open access
PFPaolo Ferrari
Paolo Ferrari
FBF. Becker
F. Becker
JDJ. Dabin
J. Dabin
JEJonathan Eakins
Jonathan Eakins
ZJZ. Jovanović
Z. Jovanović
FFF. Fioroni
F. Fioroni
In the last decades, new technologies and new radiopharmaceuticals for diagnosis and therapy have continuously grown, and that growth was accompanied by an increasing use in clinical practice, but, as with any other application involving radiation, the extent to which they may contribute to increasing the radiation dose to the operator must be studied. For that reason, EURADOS (European Radiation Dosimetry Group) decided to evaluate the exposure of medical staff in nuclear medicine to new possible radiopharmaceuticals labelled with Sc-47 and Cu-67. Modified ICRP voxel model were employed to determine the exposure of the eye lens and of the thyroid of operators administrating radiopharmaceuticals in a typical Peptide Receptor Radionuclide Therapy scenario. The simulations were validated comparing Monte Carlo results with TLD measurements performed in hospital with Lu-177 labelled compounds. Doses to the eye lens and thyroid are derived from the photon emissions (the beta contribution is three order of magnitude lower). The agreement obtained for Lu-177 provides confidence that, notwithstanding the limits of the simulations, the robustness of the followed approach can be extended also to the evaluation performed for Sc-47 and Cu-67. The dose to the lens of the eye is of the order of 2 µSv/GBq per patient for Lu-177 compounds and, due to the different energies and yields, about 8 µSv/GBq for both Sc-47 and Cu-67. These evaluations can be useful to optimize the radiation protection of medical staff in the nuclear medicine environment and assess the correct personnel workload in these kinds of practices.

7 July 2026 in Journal of Radiological Protection
Verified
Journal Article
Closed access
RKRobert Kollaard
Robert Kollaard
ŁAŁukasz Albiniak
Łukasz Albiniak
NCNicolas Cherbuin
Nicolas Cherbuin
JDJérémie Dabin
Jérémie Dabin
HDHanan Datz
Hanan Datz
EAElse Aalbersberg
Else Aalbersberg
Despite the increased use of 177 Lu in nuclear medicine (NM) over the last 10 years, the knowledge of the actual exposure of the extremities due to manipulation of this pharmaceutical is limited. The purpose of this study is to assess the extremity dose during the preparation and administration of 177 Lu-labelled radiopharmaceuticals in a wide range of NM practices. Workers in 10 NM centres throughout Europe wore a ring dosimeter on the base of the index finger of the non-dominant hand during preparation and/or administration of 177 Lu-labelled radiopharmaceuticals. Information on manipulated activity, tasks performed and protection measures was collected to allow sub-analyses. The median ring dose per monitoring interval was 0.16 mSv, with a maximum of 2.27 mSv in one month. The median normalised dose amounted 3.5 µ Sv GBq −1 (range 0.5–525). The highest monthly doses were found for workers involved in preparation of the pharmaceutical. The workers performing manual administrations (6.5 µ Sv GBq −1 ) showed higher normalised ring doses than those using the gravity method (3.5 µ Sv GBq −1 ) or a syringe pump (1.0 µ Sv GBq −1 ). Explanations for the wide range of normalised ring doses may be found in the different techniques applied in this study and the differences in minimum reportable doses of the dosimeters. When the data is extrapolated using a fingertip to ring dose ratio of 5, an annual fingertip dose of 1–136 mSv is found, with a median fingertip dose of 10 mSv per year. Extremity exposure during 177 Lu handling remained well below dose limits. The highest normalised doses occurred during preparation and manual administration. Overall, this investigation shows doses remain low when appropriate radiation protection measures (e.g. shielding and minimising time at short distance) are being applied.

16 December 2025 in Physica Medica
Verified
Journal Article
Closed access
AMAnn McCann
Ann McCann
MCMathilde Colombie
Mathilde Colombie
LVLuis León Vintró
Luis León Vintró
SCSeán Cournane
Seán Cournane
HAHussein Almeamar
Hussein Almeamar
JLJulie Lucey
Julie Lucey